Erlotinib

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Erlotinib
   1. Pharmacist Assessment Report
   2. Erlotinib: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Erlotinib: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Erlotinib, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	6
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
malignant tumor	licence in another country
non-small-cell lung carcinoma	licence in another country
pancreatic neoplasms	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
lung cancer
non-small cell lung carcinoma
pancreatic adenocarcinoma

Australia Market Information

Licence	Product	Dosage form	Status
10014C	Erlotinib Sandoz	Tablet 150 mg (as hydrochloride)	Valid

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (EGFR tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the PI. Liver function, renal function and electrolytes are relevant given the contraindication associations listed below.
Handling Protection	Please refer to the PI and local cytotoxic drug handling policies

Safety Considerations

• Disease associations flagged in the knowledge graph (not label text): The TxGNN knowledge graph links erlotinib with caution or contraindication in several conditions. These include:
  • liver and kidney disease, hepatorenal syndrome, hyperbilirubinaemia and Gilbert syndrome
  • interstitial lung disease and pulmonary fibrosis
  • thrombocytopenia and other blood coagulation disorders
  • stroke, myocardial infarction and coronary artery disease
  • corneal ulcer

  These should be verified against the TGA-approved PI.

• Drug Interactions: 100 interactions were identified. The main ones are:
  • Major: proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole), which reduce erlotinib absorption by raising gastric pH.
  • Moderate: H2 blockers (famotidine, ranitidine, cimetidine, nizatidine), antacids (aluminium hydroxide, calcium carbonate, magnesium oxide, magaldrate), dexamethasone, clarithromycin, miconazole, naltrexone, eliglustat and rolapitant.

Please refer to the TGA-approved Product Information (PI) for the official warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---